Table 1.
Patient characteristics.
| All patients, n=83 (%) | |
|---|---|
| Age (years), median (IQR) | 64 (58-70) |
| Sex, male | 47 (57) |
| Stage of disease | |
| Resectable or borderline resectable
Locally advanced Metastatic |
28 (34) 35 (42) 20 (24) |
| Responsea to FOLFIRINOX | |
|
Stable disease
Partial response Progressive disease |
54 (65) 10 (12) 19 (23) |
| Responsea to FOLFIRINOX, dichotomized | |
|
Disease control
Progressive disease |
64 (77) 19 (23) |
| Time point of CT evaluation progressive disease* (n=19) | |
|
After cycle 1
After cycle 2 After cycle 3 After cycle 4 After cycle 6 After cycle 8 |
1 (5) 3 (16) 2 (11) 9 (47) 1 (5) 3 (16) |
| Number of cycles of FOLFIRINOX received, median (IQR) | 8 (4-8) |
| Baseline CA19-9 (kU/L), median (IQR) | 320 (60-1296) |
CA19-9, carbohydrate antigen 19-9; IQR, interquartile range. aAccording to the RECIST 1.1 criteria.